VectorGen is a New York–based biotechnology company developing next‑generation gene delivery platforms designed to unlock curative therapies for complex diseases. Our core technology integrates engineered viral vectors with rational protein design to achieve highly efficient, cell‑specific delivery while overcoming the biological bottlenecks that limit current gene therapy modalities. This platform enables in vivo genetic interventions that are safer, more precise, and more scalable than existing approaches.

Our lead program focuses on an in vivo gene‑delivery system intended to eradicate HIV reservoirs in persons living with the virus, offering a path toward functional cure. Beyond HIV, VectorGen is advancing a pipeline of applications in infectious disease, oncology, and regenerative medicine, each leveraging the same modular delivery architecture.

VectorGen is committed to contributing to New York’s rapidly expanding life‑science ecosystem by building translational partnerships, supporting clinical innovation, and accelerating the development of curative genetic medicines. We aim to bring transformative therapies from concept to clinic through rigorous science, strategic collaboration, and a clear focus on patient impact.